Table 2.
Overall survival analysis in AIS patients and subgroups
| Group | Gender | E2A-PBX1 status | Patient number | Median survival (months) | 95% CI | P value |
|---|---|---|---|---|---|---|
| AIS patients |
Female |
|
53 |
105.60 |
63.95 ~ 147.25 |
0.0378 |
| |
Male |
|
23 |
56.20 |
22.34 ~ 90.06 |
|
| AIS patients with E2A-PBX1 |
Female |
|
12 |
56.20 |
37.46 ~ 74.94 |
0.6401 |
| |
Male |
|
5 |
56.20 |
0.00 ~ 122.80 |
|
| AIS patients without E2A-PBX1 |
Female |
|
41 |
105.60 |
63.45 ~ 147.75 |
0.0345 |
| |
Male |
|
18 |
NR |
NA |
|
| AIS patients |
|
+ |
17 |
56.20 |
44.37 ~ 68.03 |
0.1235 |
| |
|
- |
59 |
105.60 |
63.95 ~ 147.25 |
|
| AIS stage I patients |
|
+ |
10 |
56.20 |
38.38 ~ 74.02 |
0.1753 |
| |
|
- |
41 |
105.60 |
63.65 ~ 147.55 |
|
| AIS female patients |
|
+ |
12 |
56.20 |
37.46 ~ 74.94 |
0.0747 |
| |
|
- |
41 |
105.60 |
63.45 ~ 147.75 |
|
| AIS stage IA patients |
|
+ |
6 |
NR |
NA |
0.0363 |
| |
|
- |
18 |
NR |
NA |
|
| AIS stage IA female patients |
|
+ |
4 |
46.70 |
8.77 ~ 84.63 |
0.0174 |
| - | 13 | 105.60 | NA |
NR: not reached; NA: not available.